Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis

IntroductionTeriparatide (TPTD), a widely used bone-promoting drug in osteoporosis (OP) treatment, may cause compensatory bone resorption with long-term monotherapy (>6 months). Combining TPTD with anti-bone resorption drugs (e.g., bisphosphonates and denosumab) could reduce bone loss, yet ex...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Huan Jin, Cai Huang, Yan Zhang, Ying Dong, Qi Xiong, Di Wang, Ziyi He, Lin Shen, Chen Ma, Zixian Wang, Bo Shuai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	osteoporosis teriparatide monotherapy bisphosphonates denosumab vertebral fractures bone mineral density
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1605279/full